This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor:—
In our recent article on the treatment of idiopathic thrombocytopenic purpura (ITP) with prednisone (J. A. M. A. 166:1805-1815 [April 12] 1958), we noted in an addendum that two additional patients with ITP treated with triamcinolone showed excellent hematologic responses. Further observations indicated that the latter product had hematological effects resembling closely those obtained with prednisone. Subsequent use of this product indicates that in the relatively high doses required in our patients, a rather high incidence of a variety of nonhematological reactions occurred. As a result, we are reappraising its usefulness when administered in the dosages required for the therapy of the various hematological disorders. Sixteen consecutive patients with hematological disease (ITP, autoimmune hemolytic anemia, and leukemia) were treated with triamcinolone in maximal dosages varying from 12 to 100 mg. daily. The latter dosage was used in only one patient (with severe autoimmune hemolytic anemia); in six
Dameshek W, Rubio F. DRUG REACTIONS. JAMA. 1958;167(17):2117–2118. doi:10.1001/jama.1958.02990340077016
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: